FDA places partial hold on Bright Minds Biosciences study amid toxicity findings
What happened
The FDA placed a partial hold on the BMB-101-105 study for Bright Minds Biosciences Inc. due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This decision delays the development of BMB-101 for developmental and epileptic encephalopathies. Concurrently, Benchmark and Jefferies Financial Group reaffirmed buy ratings for the company.
From themarketsdaily.com
Why it matters
The FDA's hold raises concerns about the drug’s safety profile and may require Bright Minds Biosciences Inc. to provide additional studies, potentially increasing development costs and extending timelines. This clinical setback occurred while analyst firms Benchmark and Jefferies Financial Group maintained positive investment ratings.
From themarketsdaily.com
Who's involved
- FDACited toxicity findings and placed a partial hold on the BMB-101-105 study.
- BenchmarkReaffirmed a buy rating for Bright Minds Biosciences Inc.
- Jefferies Financial GroupReaffirmed a buy rating for Bright Minds Biosciences Inc.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Royal Bank of CanadaSpeculative
Royal Bank of Canada might see the value of its investment positions decrease due to the stock drop of Bright Minds Biosciences Inc.
Keep exploring
The entities involved
-
Benchmark
venture capital firm
-
Jefferies Financial Group
American financial services company
- FDA
Related events
- Benchmark reaffirmed a buy rating on the stock of Alpha Tau Medical.
- Analyst rating updates for Krystal Biotech, including a buy rating from TD Cowen and a consensus rating from MarketBeat.
- Jefferies Financial Group restated a buy rating on Wise shares.
- Jefferies, Citigroup, and Leerink Partners issued rating updates and price targets for Phathom Pharmaceuticals.
- Benchmark reissued a buy rating on SFL Corporation Ltd. shares.